Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab Plus Apatinib Combined With GEMOX in the Perioperative Treatment of Locally Advanced Biliary Tract Malignancies
NCT05451290Phase 2Active, not recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Nov 2022
- Primary completion
- Dec 2024
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab, Rivoceranib in biliary tract carcinoma (BTC), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Started Nov 2022; status: active, not recruiting.
02
Drugs
camrelizumabRivoceranib
03
Conditions
biliary tract carcinoma (BTC)
Beyond the preview
Go deeper on NCT05451290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05451290.